Trial Details 125 Total Sites

A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.

phase

Phase 3

status

Recruiting

enrollment

984

score

60

start date

2020-02-06

last updated

2022-01-06

biomarkers

N/A

Los Angeles, California
facility
UCLA Medical Center
1 facility
Recruiting
Houston, Texas
facility
University of Texas MD Anderson Cancer Clinic
facility
(USOR) Texas Oncology, P.A.
2 facilities
Recruiting
San Antonio, Texas
facility
Urology San Antonio P.A.
1 facility
Recruiting
Dallas, Texas
facility
Texas Oncology, P.A.
1 facility
Recruiting
Austin, Texas
facility
Texas Oncology, P.A.
1 facility
Recruiting
Columbus, Ohio
facility
Ohio State University
1 facility
Recruiting
Seattle, Washington
facility
Local Institution
facility
Seattle Cancer Care Alliance
2 facilities
Recruiting
Denver, Colorado
facility
The Urology Center of Colorado
1 facility
Recruiting
Baltimore, Maryland
facility
University of Maryland Greenebaum Cancer Center
1 facility
Recruiting
Washington, Washington, D.C.
facility
MedStar Washington Hospital Center
1 facility
Recruiting
Tucson, Arizona
facility
Local Institution
facility
The University of Arizona Cancer Center
2 facilities
Recruiting
Atlanta, Georgia
facility
Blood Marrow Transplant Group of Georgia at Northside Hospital (Cumming)
1 facility
Recruiting